Identification of the early VIP-regulated transcriptome and its associated, interactome in resting and activated murine CD4 T cells

Molecular Immunology

Volumn 47, Issue 6, 2010, Pages 1181-1194

  Dorsam, Sheri Tinnell ^a   Vomhof DeKrey, Emilie ^a   Hermann, Rebecca J ^a   Haring, Jodie S ^a   Van der Steen, Travis ^a   Wilkerson, Erich ^a   Boskovic, Goran ^b   Denvir, James ^b,d   Dementieva, Yulia ^b,c   Primerano, Donald ^b   Dorsam, Glenn Paul ^a  

^a NORTH DAKOTA STATE UNIVERSITY   (United States)

^b MARSHALL UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MARSHALL UNIVERSITY   (United States)

^d WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

EGFR; Fos; Microarray; Regulatory T cells; T cell homing; Vasoactive intestinal peptide; Vasoactive intestinal peptide receptor 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN FOS; TRANSCRIPTOME; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CONTROLLED STUDY; FEMALE; GENE CONTROL; GENE EXPRESSION; GENOME ANALYSIS; IMMEDIATE EARLY GENE; IMMUNOREGULATION; LYMPHOCYTE HOMING; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RNA HYBRIDIZATION; RNA ISOLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE; VASOACTIVE INTESTINAL PEPTIDE;

MURINAE;

EID: 76949085276     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2010.01.003     Document Type: Article

References (74)

1. Abad C., Juarranz Y., Martinez C., Arranz A., Rosignoli F., Garcia-Gomez M., Leceta J., and Gomariz R.P. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 11 (2005) 674-684
2. Abad C., Martinez C., Juarranz M.G., Arranz A., Leceta J., Delgado M., and Gomariz R.P. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124 (2003) 961-971
3. 2+ ionophore in activation of protein kinase C (PKC)alpha and PKC beta isoenzymes in human T cells and in induction of related cellular functions. Immunology 76 (1992) 465-471
4. Arranz A., Gutierrez-Canas I., Carrion M., Juarranz Y., Pablos J.L., Martinez C., and Gomariz R.P. VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts. Mol. Immunol. 45 (2008) 3065-3073
5. Ben-Horin S., and Chowers Y. Neuroimmunology of the gut: physiology, pathology, and pharmacology. Curr. Opin. Pharmacol. 8 (2008) 490-495
6. Benton K.D., Hermann R.J., Vomhof-Dekrey E.E., Haring J.S., Van der Steen T., Smith J., Dovat S., and Dorsam G.P. A transcriptionally permissive epigenetic landscape at the vasoactive intestinal peptide receptor-1 promoter suggests a euchromatin nuclear position in murine CD4 T cells. Regul. Pept. 158 1-3 (2009) 68-76
7. Birchmeier W., and Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta 1198 (1994) 11-26
8. Bodor J., Fehervari Z., Diamond B., and Sakaguchi S. ICER/CREM-mediated transcriptional attenuation of IL-2 and its role in suppression by regulatory T cells. Eur. J. Immunol. 37 (2007) 884-895
9. Bokaei P.B., Ma X.Z., Byczynski B., Keller J., Sakac D., Fahim S., and Branch D.R. Identification and characterization of five-transmembrane isoforms of human vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors. Genomics 88 (2006) 791-800
10. Buhrer C., Berlin C., Thiele H.G., and Hamann A. Lymphocyte activation and expression of the human leucocyte-endothelial cell adhesion molecule 1 (Leu-8/TQ1 antigen). Immunology 71 (1990) 442-448
11. Cahill M.A., Ernst W.H., Janknecht R., and Nordheim A. Regulatory squelching. FEBS Lett. 344 (1994) 105-108
12. Calvano S.E., Xiao W., Richards D.R., Felciano R.M., Baker H.V., Cho R.J., Chen R.O., Brownstein B.H., Cobb J.P., Tschoeke S.K., Miller-Graziano C., Moldawer L.L., Mindrinos M.N., Davis R.W., Tompkins R.G., and Lowry S.F. A network-based analysis of systemic inflammation in humans. Nature 437 (2005) 1032-1037
13. Charrier-Hisamuddin L., Laboisse C.L., and Merlin D. ADAM-15: a metalloprotease that mediates inflammation. FASEB J. 22 (2008) 641-653
14. Chen G., Hao J., Xi Y., Wang W., Wang Z., Li N., and Li W. The therapeutic effect of vasoactive intestinal peptide on experimental arthritis is associated with CD4+ CD25+ T regulatory cells. Scand. J. Immunol. 68 (2008) 572-578
15. Crabtree G.R., and Clipstone N.A. Signal transmission between the plasma membrane and nucleus of T lymphocytes. Annu. Rev. Biochem. 63 (1994) 1045-1083
16. Dautzenberg F.M., Mevenkamp G., Wille S., and Hauger R.L. N-terminal splice variants of the type I PACAP receptor: isolation, characterization and ligand binding/selectivity determinants. J. Neuroendocrinol. 11 (1999) 941-949
17. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7 (2001) 563-568
18. Delgado M., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit expression of Fas ligand in activated T lymphocytes by regulating c-Myc, NF-kappa B, NF-AT, and early growth factors 2/3. J. Immunol. 166 (2001) 1028-1040
19. Delgado M., Martinez C., Johnson M.C., Gomariz R.P., and Ganea D. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 68 (1996) 27-38
20. Delgado M., Pozo D., and Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56 (2004) 249-290
21. Duning K., Schurek E.M., Schluter M., Bayer M., Reinhardt H.C., Schwab A., Schaefer L., Benzing T., Schermer B., Saleem M.A., Huber T.B., Bachmann S., Kremerskothen J., Weide T., and Pavenstadt H. KIBRA modulates directional migration of podocytes. J. Am. Soc. Nephrol. 19 (2008) 1891-1903
22. El Zein N., Badran B., and Sariban E. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1. J. Leukoc. Biol. 83 (2008) 972-981
23. Gendronneau G., Sidhu S.S., Delacour D., Dang T., Calonne C., Houzelstein D., Magnaldo T., and Poirier F. Galectin-7 in the control of epidermal homeostasis after injury. Mol. Biol. Cell 19 (2008) 5541-5549
24. Goicoechea S.M., Bednarski B., Garcia-Mata R., Prentice-Dunn H., Kim H.J., and Otey C.A. Palladin contributes to invasive motility in human breast cancer cells. Oncogene 28 (2009) 587-598
25. Gonzalez-Rey E., and Delgado M. Vasoactive intestinal peptide inhibits cyclooxygenase-2 expression in activated macrophages, microglia, and dendritic cells. Brain Behav. Immun. 22 (2008) 35-41
26. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Martin J., Pozo D., Ganea D., and Delgado M. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses. Am. J. Pathol. 168 (2006) 1179-1188
27. Grier III C.E., and Mastro A.M. Phorbol ester circumvents the need for macrophages as well as for mitogenic lectins in the stimulation of lymphocytes with wheat germ agglutinin or the calcium ionophores A23187 or ionomycin. J. Leukoc. Biol. 40 (1986) 511-523
28. Guo D., Tan Y.C., Wang D., Madhusoodanan K.S., Zheng Y., Maack T., Zhang J.J., and Huang X.Y. A Rac-cGMP signaling pathway. Cell 128 (2007) 341-355
29. Hamidi S.A., Prabhakar S., and Said S.I. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur. Respir. J. 31 (2008) 135-139
30. Holt L.J., and Daly R.J. Adapter protein connections: the MRL and Grb7 protein families. Growth Factors 23 (2005) 193-201
31. Jiang X., Jing H., and Ganea D. VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J. Neuroimmunol. 133 (2002) 81-94
32. Johnson M.C., McCormack R.J., Delgado M., Martinez C., and Ganea D. Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J. Neuroimmunol. 68 (1996) 109-119
33. Johnston J.A., Taub D.D., Lloyd A.R., Conlon K., Oppenheim J.J., and Kevlin D.J. Human T lymphocyte chemotaxis and adhesion induced by vasoactive intestinal peptide. J. Immunol. 153 (1994) 1762-1768
34. Keino H., Kezuka T., Takeuchi M., Yamakawa N., Hattori T., and Usui M. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch. Ophthalmol. 122 (2004) 1179-1184
35. Kook Y.H., Adamski J., Zelent A., and Ossowski L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J. 13 (1994) 3983-3991
36. Kopp J.L., Ormsbee B.D., Desler M., and Rizzino A. Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 26 (2008) 903-911
37. Lara-Marquez M., O'Dorisio M., O'Dorisio T., Shah M., and Karacay B. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 166 (2001) 2522-2530
38. Li H., Mei Y., Wang Y., and Xu L. Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J. Clin. Immunol. 26 (2006) 430-437
39. Manser J., Roonprapunt C., and Margolis B. C. elegans cell migration gene mig-10 shares similarities with a family of SH2 domain proteins and acts cell nonautonomously in excretory canal development. Dev. Biol. 184 (1997) 150-164
40. Margolis B., Silvennoinen O., Comoglio F., Roonprapunt C., Skolnik E., Ullrich A., and Schlessinger J. High-efficiency expression/cloning of epidermal growth factor-receptor-binding proteins with Src homology 2 domains. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 8894-8898
41. Masquilier D., and Sassone-Corsi P. Transcriptional cross-talk: nuclear factors CREM and CREB bind to AP-1 sites and inhibit activation by Jun. J. Biol. Chem. 267 (1992) 22460-22466
42. Mazzieri R., D'Alessio S., Kenmoe R.K., Ossowski L., and Blasi F. An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. Mol. Biol. Cell 17 (2006) 367-378
43. Nakakura E.K., Watkins D.N., Schuebel K.E., Sriuranpong V., Borges M.W., Nelkin B.D., and Ball D.W. Mammalian scratch: a neural-specific Snail family transcriptional repressor. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4010-4015
44. Newman R., Cuan N., Hampartzoumian T., Connor S.J., Lloyd A.R., and Grimm M.C. Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis. Clin. Exp. Immunol. 139 (2005) 411-420
45. Nikolic M. The Pak1 kinase: an important regulator of neuronal morphology and function in the developing forebrain. Mol. Neurobiol. 37 (2008) 187-202
46. Nusrat A.R., and Chapman Jr. H.A. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest. 87 (1991) 1091-1097
47. Ottaway C.A. In vitro alteration of receptors for vasoactive intestinal peptide changes the in vivo localization of mouse T cells. J. Exp. Med. 160 (1984) 1054-1069
48. Ottaway C.A. Selective effects of vasoactive intestinal peptide on the mitogenic response of murine T cells. Immunology 62 (1987) 291-297
49. Ottaway C.A., Lewis D.L., and Asa S.L. Vasoactive intestinal peptide-containing nerves in Peyer's patches. Brain Behav. Immun. 1 (1987) 148-158
50. Pozo D., Anderson P., and Gonzalez-Rey E. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J. Immunol. 183 (2009) 4346-4359
51. Richter W.O., Robl H., and Schwandt P. Human glucagon and vasoactive intestinal polypeptide (VIP) stimulate free fatty acid release from human adipose tissue in vitro. Peptides 10 (1989) 333-335
52. Sabo S.L., Ikin A.F., Buxbaum J.D., and Greengard P. The Alzheimer amyloid precursor protein (APP) and FE65, an APP-binding protein, regulate cell movement. J. Cell Biol. 153 (2001) 1403-1414
53. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., Li J., Thiagarajan M., White J.A., and Quackenbush J. TM4 microarray software suite. Methods Enzymol. 411 (2006) 134-193
54. Said S.I., and Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 169 (1970) 1217-1218
55. Sandig H., Pease J.E., and Sabroe I. Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function. J. Leukoc. Biol. 81 (2007) 372-382
56. Shah S., and Qiao L. Resting B cells expand a CD4+ CD25+ Foxp3+ Treg population via TGF-beta3. Eur. J. Immunol. 38 (2008) 2488-2498
57. Sharma V., Delgado M., and Ganea D. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J. Immunol. 176 (2006) 97-110
58. Sheng B., Song B., Zheng Z., Zhou F., Lu G., Zhao N., Zhang X., and Gong Y. Abnormal cleavage of APP impairs its functions in cell adhesion and migration. Neurosci. Lett. 450 (2009) 327-331
59. Soltau J., and Drevs J. Mode of action and clinical impact of VEGF signaling inhibitors. Expert Rev. Anticancer Ther. 9 (2009) 649-662
60. Tamir A., Granot Y., and Isakov N. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. J. Immunol. 157 (1996) 1514-1522
61. Tanaka M., Nanba D., Mori S., Shiba F., Ishiguro H., Yoshino K., Matsuura N., and Higashiyama S. ADAM binding protein Eve-1 is required for ectodomain shedding of epidermal growth factor receptor ligands. J. Biol. Chem. 279 (2004) 41950-41959
62. Tang N., and Ostap E.M. Motor domain-dependent localization of myo1b (myr-1). Curr. Biol. 11 (2001) 1131-1135
63. Truneh A., Albert F., Golstein P., and Schmitt-Verhulst A.M. Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 313 (1985) 318-320
64. Tull S.P., Yates C.M., Maskrey B.H., O'Donnell V.B., Madden J., Grimble R.F., Calder P.C., Nash G.B., and Rainger G.E. Omega-3 fatty acids and inflammation: novel interactions reveal a new step in neutrophil recruitment. PLoS Biol. 7 (2009) e1000177
65. Tusher V.G., Tibshirani R., and Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 5116-5121
66. Valdehita A., Bajo A.M., Schally A.V., Varga J.L., Carmena M.J., and Prieto J.C. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells. Mol. Cell. Endocrinol. 302 (2009) 41-48
67. Valenzuela-Fernandez A., Cabrero J.R., Serrador J.M., and Sanchez-Madrid F. HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol. 18 (2008) 291-297
68. Voice J., Donnelly S., Dorsam G., Dolganov G., Paul S., and Goetzl E.J. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J. Immunol. 172 (2004) 7289-7296
69. Vomhof-DeKrey E.E., and Dorsam G.P. Stimulatory and suppressive signal transduction regulates vasoactive intestinal peptide receptor-1 (VPAC-1) in primary mouse CD4 T cells. Brain Behav. Immun. 22 (2008) 1024-1031
70. Vomhof-DeKrey E.E., Hermann R.J., Palmer M.F., Benton K.D., Sandy A.R., Dorsam S.T., and Dorsam G.P. TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells. Brain Behav. Immun. 22 (2008) 1032-1040
71. Wang H.Y., Jiang X.M., and Ganea D. The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J. Neuroimmunol. 104 (2000) 68-78
72. Wang W., Reeves W.B., and Ramesh G. Netrin-1 increases proliferation and migration of renal proximal tubular epithelial cells via the UNC5B receptor. Am. J. Physiol. Renal Physiol. 296 (2009) F723-F729
73. Yang Z., Bagheri-Yarmand R., Wang R.A., Adam L., Papadimitrakopoulou V.V., Clayman G.L., El-Naggar A., Lotan R., Barnes C.J., Hong W.K., and Kumar R. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin. Cancer Res. 10 (2004) 658-667
74. Yang Z., Rayala S., Nguyen D., Vadlamudi R.K., Chen S., and Kumar R. Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res. 65 (2005) 3179-3184